As­traZeneca sweeps two can­cer drugs to the scrap heap; Epizyme nabs pri­or­i­ty re­view for sec­ond rare can­cer NDA

As­traZeneca swept out two ear­ly-stage can­cer drugs in its Q4 call on Fri­day. Out to the dust­bin goes the an­ti-AS­CT2 an­ti­body-drug con­ju­gate ME­DI7247 and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA